Effervescent tablet formulation for enhanced patient compliance and the therapeutic effect of risperidone

References

• Bourne DWA. (2002). Pharmacokinetics. In: Banker GS, Rhodes CT, ed. Modern pharmaceutics. 4th ed. New York: Marcel Dekker Inc., 67–92
   Google Scholar
• Boxenbaum H. (1998). Pharmacokinetics tricks and traps: flip-flop models. J Pharm Pharm Sci 1:90–1
   PubMedGoogle Scholar
• Castelli F, Sarpietro MG, Micieli D, et al. (2008). Differential scanning calorimetry study on drug release from an inulin-based hydrogel and its interaction with a biomembrane model: pH and loading effect. Eur J Pharm Sci 35:76–85
   PubMed Web of Science ®Google Scholar
• Chereson R. (1996). Bioavailability, Bioequivalence and Drug Selection. Basic Pharmacokinetics, ed. M.C. Makoid
   Google Scholar
• Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123–33
   PubMed Web of Science ®Google Scholar
• Damian F, Blaton N, Naesens L, et al. (2000). Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur J Pharm Sci 10:311–22
   PubMed Web of Science ®Google Scholar
• Duquesnoy C, Lacey LF, Keene ON, Bye A. (1998). Evaluation of different partial AUCs as indirect measures of rate of drug absorption in comparative pharmacokinetic studies. Eur J Pharm Sci 6:259–64
   PubMed Web of Science ®Google Scholar
• El-Zein H, Riad L, El-Bary AA. (1998). Enhancement of carbamazepine dissolution: in vitro and in vivo evaluation. Int J Pharm 168:209–20
   Web of Science ®Google Scholar
• Endrenyi L, Fritsch S, Yan W. (1991). Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 29:394–9
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Lacombe S. (1993). Pharmacological profile of risperidone. Can J Psychiatry 38:S80–8
   PubMed Web of Science ®Google Scholar
• FDA. (October 6, 2006). FDA approves the first drug to treat irritability associated with autism, Risperdal. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm [last accessed 14 August 2009]
   Google Scholar
• Hancock BC, Zografi G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1–12
   PubMed Web of Science ®Google Scholar
• Harkness JE, Wagner JE. (1989). The biology and medicine of rabbits and rodents. Philadelphia: Lea and Febiger
   Google Scholar
• Huang ML, Van Peer A, Woestenborghs R, et al. (1993). Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257–68
   PubMed Web of Science ®Google Scholar
• Jones B, Kenward MG. (2003). Design and analysis of cross-over trials (Second ed.). London: Chapman and Hall
   Google Scholar
• Kearney AS, Gabriel DL, Mehta SC, et al. (1994). Effect of polyvinylpyrrolidone on the crystallinity and dissolution rate of solid dispersions of the antiinflammatory CI-987. Int J Pharm 104:169–74
   Web of Science ®Google Scholar
• Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol 27:48–9
   PubMed Web of Science ®Google Scholar
• Khan KA, Rhodes CT. (1972). Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv 47:594–607
   PubMedGoogle Scholar
• Lacey LF, Keene ON, Duquesnoy C, Bye A. (1994). Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J Pharm Sci 83:212–15
   PubMed Web of Science ®Google Scholar
• Lachman L, Lieberman HA, Kanig JL. (1986). The theory and practice of industrial pharmacy. Philadelphia: Lea & Febiger
   Google Scholar
• Lo WY, Law SL. (1996). Dissolution behavior of griseofulvin solid dispersions using polyethylene glycol, talc, and their combination as dispersion carriers. Drug Dev Ind Pharm 22:231–6
   Web of Science ®Google Scholar
• Macheras P, Symillides M, Reppas C. (1993). Estimation of absorption rate constant in a one-compartment model with the profile of the bioavailable dose eliminated as a function of multiples of half-life. J Pharm Sci 82:1298–300
   PubMed Web of Science ®Google Scholar
• Sweetman SC. (2009). Martindale: the complete drug reference. London: Chicago, Pharmaceutical Press, 1024–7
   Google Scholar
• Naima ZT. Siro T, Juan-Manuel GD, et al. (2001). Interactions between carbamazepine and polyethylene glycol (PEG) 6000: characterisations of the physical, solid dispersed and eutectic mixtures. Eur J Pharm Sci 12:395–404
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. (1997). Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Sci Appl 698:209–16
   PubMed Web of Science ®Google Scholar
• Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110–11
   PubMedGoogle Scholar
• Rahman Z, Zidan AS, Khan MA. (2010). Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation. Int J Pharm 400:49–58
   PubMed Web of Science ®Google Scholar
• Rowe RC, Shesky PJ, Quinn ME. (2009). Handbook of pharmaceutical excipients. Pharmaceutical Press: London
   Google Scholar
• Sedgwick GW, Fenton TW, et al. (1991). Effect of protein precipitating agents on the recovery of plasma free amino acids. Can J Anim Sci 71:953–7
   Web of Science ®Google Scholar
• Seltzer A, Hoffman BF. (1980). Drug compliance and the psychiatric patient. Can Fam Physician 26:725–7
   PubMed Web of Science ®Google Scholar
• Skoog DA. (1998). Principles of instrumental analysis: introduction. Orlando (FL): Harcourt Brace, 18
   Google Scholar
• Taj R, Khan S. (2005). A study of reasons of non-compliance to psychiatric treatment. J Ayub Med Coll Abbottabad 17:26–8
   PubMedGoogle Scholar
• Thiessen JJ. (2004). Bioavailability and bioequivalence. Irvine: IUPHAR
   Google Scholar
• Tozer TN, Bois FY, Hauck WW, et al. (1996). Absorption rate vs. exposure: which is more useful for bioequivalence testing? Pharm Res 13:453–6
   PubMed Web of Science ®Google Scholar
• Weisbroth SH, Flatt RE, Kraus AL. (1974). The biology of the laboratory rabbit. New York: Academic Press
   Google Scholar
• Zajc N, Obreza A, Bele M, Srcic S. (2005). Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method. Int J Pharm 291:51–8
   PubMed Web of Science ®Google Scholar